medroxyprogesterone has been researched along with Epithelial Ovarian Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y; Liao, H; Sun, Y; Wang, Q; Yi, X; Zhang, Z; Zhou, Q | 1 |
1 other study(ies) available for medroxyprogesterone and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenoma; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Gonadotropins; Humans; Luteinizing Hormone; Medroxyprogesterone; Middle Aged; Neoplasms, Glandular and Epithelial; NF-E2-Related Factor 2; Ovarian Neoplasms; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Young Adult | 2012 |